Nuvisan ICB

Nuvisan is a leading European contract research organization (CRO) and contract development and manufacturing organization (CDMO) providing integrated drug discovery and development services. The Nuvisan Innovation Center Berlin (ICB) was established in 2020 following the acquisition of Bayer's small molecule research unit, significantly expanding the company's capabilities in early-stage drug discovery. The company offers a comprehensive suite of services ranging from target identification and lead optimization to clinical trial supply and pharmaceutical manufacturing. Nuvisan's expertise spans multiple therapeutic areas, including oncology, cardiovascular diseases, and inflammation, supported by state-of-the-art laboratories and a team of over 400 scientists at the Berlin site. As a strategic partner to the pharmaceutical industry, Nuvisan provides both standalone services and fully integrated drug discovery programs.